quinine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4523	130-95-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: quinine bisulfate heptahydrate chinine qualaquin quinine quinine sulfate	An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis. Quinine is also useful in some muscular disorders, especially nocturnal leg cramps and myotonia congenita, because of its direct effects on muscle membrane and sodium channels. The mechanisms of its antimalarial effects are not well understood. Molecular weight: 324.42 Formula: C20H24N2O2 CLOGP: 2.79 LIPINSKI: 0 HAC: 4 HDO: 1 TPSA: 45.59 ALOGS: -2.99 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

quinine bisulfate heptahydrate
chinine
qualaquin
quinine
quinine sulfate

An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis. Quinine is also useful in some muscular disorders, especially nocturnal leg cramps and myotonia congenita, because of its direct effects on muscle membrane and sodium channels. The mechanisms of its antimalarial effects are not well understood.

Molecular weight: 324.42
Formula: C20H24N2O2
CLOGP: 2.79
LIPINSKI: 0
HAC: 4
HDO: 1
TPSA: 45.59
ALOGS: -2.99
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
1.50	g	O
1.50	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	111.10 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	12 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	71.07 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	1.80 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	1.90 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.30 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	11 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Aug. 12, 2005	FDA	MUTUAL PHARM CO INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug abuse	229.86	14.59	161	13620	72357	63402884
Labile blood pressure	169.33	14.59	45	13736	1744	63473497
Lipase increased	119.13	14.59	53	13728	9847	63465394
Somatic symptom disorder	89.12	14.59	30	13751	2630	63472611
Hepatic ischaemia	88.78	14.59	22	13759	642	63474599
Sacroiliitis	86.94	14.59	31	13750	3226	63472015
Haematemesis	83.59	14.59	62	13719	30350	63444891
Hepatorenal syndrome	81.75	14.59	26	13755	1906	63473335
Hepatic failure	64.64	14.59	57	13724	35599	63439642
Toxicity to various agents	62.37	14.59	154	13627	247096	63228145
Coronary artery disease	61.19	14.59	53	13728	32324	63442917
Drug ineffective	58.12	14.59	86	13695	1044679	62430562
Muscle relaxant therapy	56.84	14.59	12	13769	167	63475074
Cognitive disorder	56.41	14.59	65	13716	55750	63419491
Renal failure	55.52	14.59	95	13686	117557	63357684
Sedation complication	54.02	14.59	35	13746	13787	63461454
Coagulopathy	50.08	14.59	39	13742	20505	63454736
Hyponatraemia	47.16	14.59	86	13695	111814	63363427
Electrocardiogram QT prolonged	46.68	14.59	61	13720	59469	63415772
Hypovolaemia	46.63	14.59	29	13752	10644	63464597
Pancreatitis	46.03	14.59	55	13726	49000	63426241
Drug hypersensitivity	44.26	14.59	158	13623	310529	63164712
Duodenal ulcer	44.15	14.59	25	13756	7731	63467510
Thrombotic microangiopathy	41.90	14.59	27	13754	10534	63464707
Gastrointestinal haemorrhage	41.54	14.59	68	13713	81108	63394133
Mood altered	40.37	14.59	30	13751	14713	63460528
Drug intolerance	40.05	14.59	9	13772	308652	63166589
Creatinine renal clearance decreased	39.83	14.59	31	13750	16277	63458964
Blood calcium decreased	39.59	14.59	38	13743	26413	63448828
Infusion related reaction	39.02	14.59	4	13777	245517	63229724
Fear of eating	37.76	14.59	10	13771	382	63474859
Product dose omission issue	36.77	14.59	4	13777	234309	63240932
Post procedural haemorrhage	35.71	14.59	22	13759	7942	63467299
Fall	35.06	14.59	173	13608	392161	63083080
Off label use	34.98	14.59	58	13723	674404	62800837
Hiccups	33.59	14.59	14	13767	2217	63473024
Depressed level of consciousness	33.11	14.59	53	13728	62025	63413216
Coronary artery bypass	32.78	14.59	14	13767	2355	63472886
Orthostatic hypotension	31.41	14.59	39	13742	36121	63439120
Abdominal discomfort	30.22	14.59	16	13765	320869	63154372
Rheumatoid arthritis	29.87	14.59	9	13772	253810	63221431
Synovitis	29.81	14.59	3	13778	186915	63288326
Retinal toxicity	29.79	14.59	11	13770	1264	63473977
Rhabdomyolysis	28.36	14.59	41	13740	43910	63431331
Myocardial ischaemia	28.31	14.59	23	13758	12836	63462405
Cinchonism	27.51	14.59	4	13777	3	63475238
Fatigue	27.45	14.59	100	13681	887928	62587313
Hepatic enzyme increased	26.03	14.59	6	13775	202322	63272919
Blood sodium decreased	25.77	14.59	29	13752	24223	63451018
Nail infection	25.60	14.59	12	13769	2511	63472730
Purpura senile	25.58	14.59	8	13773	555	63474686
Left ventricular dysfunction	25.47	14.59	21	13760	11967	63463274
Tarsal tunnel syndrome	25.42	14.59	8	13773	566	63474675
Vestibular disorder	25.03	14.59	10	13771	1421	63473820
Abdominal rigidity	24.87	14.59	11	13770	2013	63473228
Swollen tongue	24.73	14.59	34	13747	34766	63440475
Vascular injury	24.66	14.59	9	13772	1001	63474240
Constipation	24.34	14.59	105	13676	224838	63250403
Oral cavity fistula	24.21	14.59	8	13773	662	63474579
Hypotension	24.15	14.59	120	13661	272484	63202757
Salivary gland enlargement	23.60	14.59	7	13774	406	63474835
Optic ischaemic neuropathy	22.99	14.59	9	13772	1213	63474028
Exostosis of jaw	22.52	14.59	9	13772	1280	63473961
Therapeutic product effect decreased	22.45	14.59	7	13774	193180	63282061
Acute kidney injury	21.96	14.59	114	13667	263301	63211940
Cerebral artery occlusion	21.94	14.59	8	13773	887	63474354
Sedation	21.89	14.59	34	13747	38775	63436466
Drug interaction	21.82	14.59	103	13678	229028	63246213
Discomfort	21.45	14.59	5	13776	167369	63307872
Hepatocellular injury	21.36	14.59	28	13753	27353	63447888
Eczema asteatotic	21.29	14.59	6	13775	290	63474951
Poor peripheral circulation	21.11	14.59	12	13769	3737	63471504
Exposed bone in jaw	21.01	14.59	11	13770	2914	63472327
Product use issue	20.74	14.59	11	13770	220509	63254732
Muscle necrosis	20.29	14.59	7	13774	661	63474580
Arthropathy	20.26	14.59	13	13768	234779	63240462
Hand deformity	19.97	14.59	5	13776	159452	63315789
Pain	19.93	14.59	88	13693	740540	62734701
Cerebrovascular accident	19.87	14.59	60	13721	107964	63367277
Haemolytic uraemic syndrome	19.67	14.59	10	13771	2493	63472748
Resorption bone increased	19.20	14.59	8	13773	1266	63473975
Arthralgia	18.31	14.59	63	13718	569647	62905594
Myocardial infarction	17.92	14.59	55	13726	99838	63375403
Ulcer	17.79	14.59	25	13756	26082	63449159
Adrenal mass	17.64	14.59	7	13774	977	63474264
Hyperkalaemia	17.18	14.59	37	13744	54166	63421075
Multiple organ dysfunction syndrome	17.15	14.59	38	13743	56714	63418527
Gastrointestinal disorder	16.66	14.59	4	13777	131235	63344006
Nephrogenic systemic fibrosis	16.49	14.59	11	13770	4545	63470696
Sinusitis	16.42	14.59	15	13766	226638	63248603
Injection site pain	16.39	14.59	4	13777	129796	63345445
Joint swelling	16.17	14.59	29	13752	327637	63147604
Swelling	15.84	14.59	22	13759	275356	63199885
Cardiac arrest	15.72	14.59	50	13731	92495	63382746
Disseminated intravascular coagulation	15.67	14.59	20	13761	19031	63456210
Vaginal discharge	15.27	14.59	14	13767	9184	63466057
Sequestrectomy	15.24	14.59	6	13775	820	63474421
International normalised ratio increased	15.07	14.59	32	13749	46393	63428848
Chest pain	15.00	14.59	89	13692	215870	63259371
Gastritis	14.85	14.59	28	13753	37275	63437966
Alopecia	14.82	14.59	32	13749	337504	63137737
Hypomagnesaemia	14.59	14.59	24	13757	28713	63446528

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug abuse	1104.48	17.01	500	7173	98596	34850662
Toxicity to various agents	280.34	17.01	277	7396	200085	34749173
Poisoning	84.68	17.01	45	7628	12181	34937077
Exposure via ingestion	58.91	17.01	21	7652	2160	34947098
Cinchonism	54.37	17.01	8	7665	7	34949251
Intentional product misuse	50.56	17.01	56	7617	45555	34903703
Compartment syndrome	45.45	17.01	19	7654	2999	34946259
Electrocardiogram U wave present	42.79	17.01	7	7666	19	34949239
Atrioventricular block	35.24	17.01	22	7651	8041	34941217
Toxic neuropathy	29.79	17.01	9	7664	550	34948708
Urine sodium decreased	29.09	17.01	7	7666	178	34949080
Mouth swelling	29.01	17.01	12	7661	1844	34947414
Drug ineffective	27.66	17.01	36	7637	456715	34492543
Agitated depression	26.86	17.01	7	7666	248	34949010
Hypomagnesaemia	26.23	17.01	28	7645	21823	34927435
Nephrogenic systemic fibrosis	25.64	17.01	14	7659	3991	34945267
Respiratory arrest	25.31	17.01	31	7642	28012	34921246
Lower respiratory tract infection	23.88	17.01	32	7641	31605	34917653
Cerebral malaria	22.27	17.01	3	7670	0	34949258
Cardiac arrest	21.83	17.01	58	7615	96101	34853157
Off label use	21.55	17.01	37	7636	419487	34529771
Unresponsive to stimuli	20.98	17.01	28	7645	27541	34921717
Confusional state	20.63	17.01	74	7599	144086	34805172
Infected skin ulcer	20.48	17.01	9	7664	1604	34947654
Muscle spasms	19.89	17.01	48	7625	74953	34874305
Tendonitis	19.24	17.01	16	7657	9124	34940134
Increased bronchial secretion	19.15	17.01	9	7664	1872	34947386
Cutaneous extramedullary haemopoiesis	18.98	17.01	3	7670	6	34949252
Lethargy	18.84	17.01	33	7640	41089	34908169
Body mass index decreased	18.43	17.01	5	7668	207	34949051
Alveolar proteinosis	18.28	17.01	6	7667	481	34948777
Blood sodium decreased	18.06	17.01	20	7653	16231	34933027
Skin induration	18.01	17.01	9	7664	2142	34947116
Blindness transient	17.71	17.01	9	7664	2217	34947041
Hypocalcaemia	17.46	17.01	24	7649	24265	34924993

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug abuse	1252.31	13.85	663	18831	162028	79562866
Toxicity to various agents	281.48	13.85	424	19070	421116	79303778
Thrombotic microangiopathy	164.97	13.85	86	19408	20083	79704811
Labile blood pressure	149.35	13.85	44	19450	2209	79722685
Somatic symptom disorder	87.01	13.85	30	19464	2507	79722387
Cinchonism	80.53	13.85	12	19482	10	79724884
Drug ineffective	79.18	13.85	89	19405	1080824	78644070
Sacroiliitis	79.06	13.85	31	19463	3723	79721171
Poisoning	75.90	13.85	57	19437	25215	79699679
Hepatic ischaemia	74.89	13.85	22	19472	1093	79723801
Haematemesis	67.10	13.85	73	19421	52191	79672703
Exposure via ingestion	63.12	13.85	29	19465	5145	79719749
Hepatorenal syndrome	62.02	13.85	27	19467	4222	79720672
Muscle relaxant therapy	55.48	13.85	12	19482	166	79724728
Off label use	53.83	13.85	87	19407	907128	78817766
Microangiopathic haemolytic anaemia	52.15	13.85	18	19476	1509	79723385
Hyponatraemia	50.66	13.85	125	19369	177723	79547171
Product dose omission issue	48.58	13.85	3	19491	247534	79477360
Sedation complication	46.29	13.85	35	19459	15634	79709260
Cognitive disorder	45.85	13.85	70	19424	69856	79655038
Acute kidney injury	44.04	13.85	246	19248	519158	79205736
Agitated depression	40.24	13.85	11	19483	420	79724474
Fall	40.03	13.85	229	19265	487400	79237494
Intentional product misuse	39.71	13.85	78	19416	95087	79629807
Rhabdomyolysis	38.83	13.85	81	19413	103050	79621844
Atrioventricular block	38.49	13.85	30	19464	14011	79710883
Blood calcium decreased	38.33	13.85	43	19451	31776	79693118
Coronary artery disease	36.67	13.85	61	19433	65413	79659481
Depressed level of consciousness	36.49	13.85	76	19418	96576	79628318
Electrocardiogram QT prolonged	36.40	13.85	73	19421	90313	79634581
Hypovolaemia	36.39	13.85	32	19462	17659	79707235
Coagulopathy	35.64	13.85	44	19450	35962	79688932
Blood sodium decreased	35.13	13.85	42	19452	33213	79691681
Fear of eating	34.72	13.85	10	19484	463	79724431
Retinal toxicity	34.53	13.85	13	19481	1398	79723496
Mood altered	34.17	13.85	31	19463	17816	79707078
Compartment syndrome	34.07	13.85	19	19475	5063	79719831
Nephrogenic systemic fibrosis	33.24	13.85	20	19474	6140	79718754
Hepatic failure	32.91	13.85	56	19438	61156	79663738
Renal failure	32.91	13.85	116	19378	200852	79524042
Swollen tongue	32.81	13.85	46	19448	42524	79682370
Creatinine renal clearance decreased	32.51	13.85	31	19463	18971	79705923
Duodenal ulcer	32.46	13.85	29	19465	16340	79708554
Cardiac arrest	32.30	13.85	104	19390	171992	79552902
Hypomagnesaemia	32.22	13.85	48	19446	46863	79678031
Rheumatoid arthritis	32.18	13.85	6	19488	208464	79516430
Infusion related reaction	30.84	13.85	9	19485	230228	79494666
Electrocardiogram U wave present	30.53	13.85	7	19487	128	79724766
Respiratory arrest	28.79	13.85	51	19443	57499	79667395
Post procedural haemorrhage	28.55	13.85	25	19469	13719	79711175
Exposed bone in jaw	27.96	13.85	15	19479	3705	79721189
Contraindicated product administered	27.89	13.85	3	19491	157535	79567359
Hypocalcaemia	27.27	13.85	46	19448	49878	79675016
Fatigue	27.22	13.85	126	19368	929601	78795293
Hepatic enzyme increased	26.64	13.85	6	19488	182604	79542290
Synovitis	26.35	13.85	3	19491	150731	79574163
Lethargy	26.22	13.85	60	19434	81232	79643662
Gastrointestinal haemorrhage	25.68	13.85	87	19407	147632	79577262
Purpura senile	25.12	13.85	8	19486	522	79724372
Tarsal tunnel syndrome	25.03	13.85	8	19486	528	79724366
Drug intolerance	24.94	13.85	17	19477	264102	79460792
Nail infection	24.81	13.85	12	19482	2387	79722507
Treatment failure	24.08	13.85	6	19488	170480	79554414
Prescription drug used without a prescription	23.97	13.85	14	19480	4071	79720823
Toxic neuropathy	23.88	13.85	9	19485	971	79723923
Myocardial ischaemia	23.37	13.85	30	19464	25489	79699405
Vascular injury	22.70	13.85	9	19485	1112	79723782
Salivary gland enlargement	22.56	13.85	7	19487	419	79724475
Cerebral malaria	21.95	13.85	3	19491	0	79724894
Exostosis of jaw	21.73	13.85	9	19485	1245	79723649
Cerebrovascular accident	21.53	13.85	85	19409	155207	79569687
Drug interaction	21.43	13.85	174	19320	415009	79309885
Liver function test abnormal	21.24	13.85	48	19446	64427	79660467
Cardiovascular disorder	21.10	13.85	24	19470	18001	79706893
Orthostatic hypotension	21.00	13.85	44	19450	56120	79668774
Therapeutic product effect decreased	20.88	13.85	7	19487	163856	79561038
Unresponsive to stimuli	20.04	13.85	43	19451	55745	79669149
Poor peripheral circulation	19.98	13.85	12	19482	3671	79721223
Blindness transient	19.50	13.85	13	19481	4763	79720131
Bradycardia	19.44	13.85	75	19419	135482	79589412
Abdominal rigidity	19.23	13.85	11	19483	3077	79721817
Oral cavity fistula	19.08	13.85	7	19487	700	79724194
Ulcer	18.24	13.85	29	19465	29943	79694951
Left ventricular dysfunction	18.10	13.85	23	19471	19338	79705556
Product use issue	17.88	13.85	15	19479	209807	79515087
Skin induration	17.72	13.85	12	19482	4513	79720381
Melaena	17.52	13.85	43	19451	60847	79664047
Injection site pain	17.52	13.85	5	19489	129833	79595061
Confusional state	17.33	13.85	135	19359	317862	79407032
Resorption bone increased	17.16	13.85	8	19486	1467	79723427
Optic ischaemic neuropathy	16.98	13.85	10	19484	2951	79721943
Coronary artery bypass	16.72	13.85	13	19481	6049	79718845
Sinusitis	16.63	13.85	14	19480	195487	79529407
International normalised ratio increased	16.61	13.85	52	19442	84669	79640225
Deafness	16.60	13.85	23	19471	21014	79703880
Hiccups	16.47	13.85	16	19478	10015	79714879
Plasmodium falciparum infection	16.42	13.85	4	19490	96	79724798
Vaginal discharge	16.36	13.85	14	19480	7449	79717445
Eczema asteatotic	16.36	13.85	6	19488	600	79724294
Weight increased	15.99	13.85	27	19467	277359	79447535
Cerebral artery occlusion	15.98	13.85	8	19486	1714	79723180
Vestibular disorder	15.97	13.85	9	19485	2446	79722448
Myocardial infarction	15.39	13.85	87	19407	184042	79540852
Lip swelling	15.23	13.85	32	19462	40879	79684015
Hallucination, visual	15.09	13.85	28	19466	32701	79692193
Alveolar proteinosis	14.82	13.85	6	19488	783	79724111
Mouth swelling	14.60	13.85	12	19482	6039	79718855
Sequestrectomy	14.31	13.85	6	19488	856	79724038
Muscle necrosis	14.20	13.85	7	19487	1451	79723443
Pericarditis	14.09	13.85	4	19490	104232	79620662
Intentional product use issue	14.07	13.85	10	19484	152102	79572792
Blindness	13.99	13.85	25	19469	28358	79696536
Neutrophil count decreased	13.87	13.85	3	19491	93956	79630938

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	M09AA72	MUSCULO-SKELETAL SYSTEM OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM Quinine and derivatives
ATC	P01BC01	ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ANTIPROTOZOALS ANTIMALARIALS Methanolquinolines
FDA EPC	N0000175482	Antimalarial
MeSH PA	D000700	Analgesics
MeSH PA	D018712	Analgesics, Non-Narcotic
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000962	Antimalarials
MeSH PA	D000977	Antiparasitic Agents
MeSH PA	D000981	Antiprotozoal Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D009125	Muscle Relaxants, Central
MeSH PA	D009465	Neuromuscular Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D018689	Sensory System Agents
CHEBI has role	CHEBI:38068	antimalarials
CHEBI has role	CHEBI:51371	muscle relaxants

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Falciparum malaria	indication	62676009	DOID:14067
Chloroquine Resistant Plasmodium Falciparum Malaria	indication
Babesiosis	off-label use	21061004	DOID:9643
Atrial flutter	contraindication	5370000
Torsades de pointes	contraindication	31722008
End stage renal disease	contraindication	46177005	DOID:784
Atrial fibrillation	contraindication	49436004	DOID:0060224
Neuromuscular block, function	contraindication	55394004
Black water fever	contraindication	56625005	DOID:14068
Acute nephropathy	contraindication	58574008
Optic neuritis	contraindication	66760008	DOID:1210
Thrombotic thrombocytopenic purpura	contraindication	78129009	DOID:10772
Myasthenia gravis	contraindication	91637004	DOID:437
Hemolytic uremic syndrome	contraindication	111407006	DOID:12554
Anemia due to enzyme deficiency	contraindication	111577008
Prolonged QT interval	contraindication	111975006
Disease of liver	contraindication	235856003	DOID:409
Hypoglycemic disorder	contraindication	237630007
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Congenital long QT syndrome	contraindication	442917000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	12.44	acidic
pKa2	8.02	Basic
pKa3	4.1	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN				WOMBAT-PK
Multidrug resistance protein 1	Transporter	P08183	MDR1_HUMAN		Ki	4.92	CHEMBL
Hemoglobin subunit alpha	Secreted	P69905	HBA_HUMAN				WOMBAT-PK
Potassium voltage-gated channel subfamily B member 2	Ion channel	Q92953	KCNB2_HUMAN	BLOCKER	IC50	4.90	IUPHAR
Solute carrier family 22 member 1	Transporter	O15245	S22A1_HUMAN		IC50	4.29	CHEMBL
Sodium channel alpha subunits; brain (Types I, II, III)	Ion channel	P35498 Q99250 Q9NY46	SCN1A_HUMAN SCN2A_HUMAN SCN3A_HUMAN		IC50	5.36	CHEMBL
Equilibrative nucleoside transporter 4	Transporter	Q7RTT9	S29A4_HUMAN	INHIBITOR	Ki	4.57	IUPHAR

External reference:

ID	Source
D08460	KEGG_DRUG
6183-68-2	SECONDARY_CAS_RN
6119-70-6	SECONDARY_CAS_RN
4018620	VANDF
4019926	VANDF
CHEBI:15854	CHEBI
QI9	PDB_CHEM_ID
CHEMBL170	ChEMBL_ID
CHEMBL2146083	ChEMBL_ID
CHEMBL2359966	ChEMBL_ID
2510	IUPHAR_LIGAND_ID
DB00468	DRUGBANK_ID
A7V27PHC7A	UNII
647128	RXNORM
5023	MMSL
5405	MMSL
84102	MMSL
d00366	MMSL
002934	NDDF
002935	NDDF
373497008	SNOMEDCT_US
47065008	SNOMEDCT_US
47857006	SNOMEDCT_US
C0034417	UMLSCUI
D011803	MESH_DESCRIPTOR_UI
3034034	PUBCHEM_CID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Quinine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3002	CAPSULE	324 mg	ORAL	ANDA	31 sections
Quinine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3002	CAPSULE	324 mg	ORAL	ANDA	31 sections
Qualaquin	HUMAN PRESCRIPTION DRUG LABEL	1	13310-153	CAPSULE	324 mg	ORAL	NDA	32 sections
QUALAQUIN	HUMAN PRESCRIPTION DRUG LABEL	1	16590-595	CAPSULE	324 mg	ORAL	NDA	32 sections
Qualaquin	HUMAN PRESCRIPTION DRUG LABEL	1	49708-153	CAPSULE	324 mg	ORAL	NDA	32 sections
QUININE SULFATE	HUMAN PRESCRIPTION DRUG LABEL	1	50742-238	CAPSULE	324 mg	ORAL	ANDA	21 sections
Quinine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	1	53489-700	CAPSULE	324 mg	ORAL	NDA authorized generic	32 sections
Quinine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	1	65162-811	CAPSULE	324 mg	ORAL	ANDA	20 sections
Quinine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	1	65162-811	CAPSULE	324 mg	ORAL	ANDA	20 sections
Quinine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	1	68084-947	CAPSULE	324 mg	ORAL	NDA authorized generic	31 sections
Quinine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	1	68084-947	CAPSULE	324 mg	ORAL	NDA authorized generic	31 sections
Quinine Sulfate	HUMAN PRESCRIPTION DRUG LABEL	1	68084-947	CAPSULE	324 mg	ORAL	NDA authorized generic	31 sections
QUININE SULFATE	HUMAN PRESCRIPTION DRUG LABEL	1	68180-560	CAPSULE	324 mg	ORAL	ANDA	20 sections
QUININE SULFATE	HUMAN PRESCRIPTION DRUG LABEL	1	68180-560	CAPSULE	324 mg	ORAL	ANDA	20 sections